Status:
UNKNOWN
Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.
Lead Sponsor:
Mansoura University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the ...
Eligibility Criteria
Inclusion
- Histologically proven breast carcinoma.
- American Society of Anesthesiology (ASA) score I-II.
- Candidate for neoadjuvant chemotherapy as per hospital's protocol.
- Clinically measurable tumor.
- No evidence of distant metastasis.
- Normal renal and liver functions.
- Non-diabetics.
Exclusion
- Pregnant or lactating women.
- Metastatic breast cancer patients.
- Patients with hepatic impairment.
- Patients with renal impairment.
- Diabetics.
- Patients unwilling to participate or withdrawing from the trial.
- Psychological/ mental impairment.
Key Trial Info
Start Date :
June 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04387630
Start Date
June 5 2020
End Date
May 1 2023
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Cancer center
Al Mansurah, Egypt, 35516